Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: phoenix_rising who wrote (1286)	6/5/2015 12:27:09 PM
From: mokelumne river	Read Replies (3) of 2026

PR I disagree with you and several others on ihub. It would have been inappropriate for Apricus to issue a press release on yesterday's FDA panel action. Different indication, for a competitor's drug, and it wasn't an FDA action. I doubt if the FDA itself was pleased at the negative (but deserved) PR they have received. Best not to inflame bureaucrats if you want your own drug to be favorably considered in the future. Apricus needs to re-engage a partner to see if they are now interested...and as Eman points out it will be likely for the EU (not US)...and sign a deal. That "surprise" will get everybody's attention.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next